E71: Russia/Ukraine deep dive: escalation, risk factors, financial fallout, exit ramps and more

The clearest red line was a NATO no-fly zone: Sacks argued it would turn support for Ukraine into direct war with Russia. NATO said on March 4 that enforcing one would require NATO fighters to shoot down Russian aircraft and could trigger a full-fledged European war. (NATO)

Chamath Palihapitiya framed the sanctions campaign as economic warfare, because finance, insurance, aircraft parts, shipping and technology could isolate Russia without NATO troops. Friedberg’s counterpoint was the collateral damage: Russia and Ukraine supplied about 25% of world wheat exports in 2021, exposing import-dependent countries to food shocks. (FAOHome)

The panel’s central strategic split was over the endgame: regime change or a negotiated ceasefire with an exit ramp for Putin. Sacks rejected regime change as an American objective, arguing sanctions relief could be bargaining leverage and that Iraq, Afghanistan, Libya and Syria showed the danger of making leadership removal the mission.

Sacks’s most controversial argument was that NATO’s open-door policy toward Ukraine materially worsened the security crisis, without proving Putin’s motives. NATO did declare in 2008 that Ukraine and Georgia “will become members”; Sacks argued shelving Ukrainian membership earlier might have reduced Putin’s justification, while conceding that prevention cannot be known. (NATO)

The episode treated wartime information itself as a strategic weapon and warned against reading early social-media claims as settled fact. The hosts cited the nuclear-plant panic, Snake Island and the “Ghost of Kyiv” as examples they believed had been distorted or overturned, while Friedberg stressed that even basic battlefield explanations remained uncertain.

Russia’s invasion had already produced a concrete European policy shift, not merely a temporary sanctions package. Germany announced a €100 billion defense fund and annual spending above 2% of GDP, which the panel read as evidence that Europe was rethinking both military preparedness and dependence on Russian energy. (Bundesregierung)

The private-market correction was already visible: the investors said late-stage “mania” was over, deals were taking longer, diligence was returning, and 100× ARR had stopped being normal. They were still seeing some software deals at 60–80× ARR, but the uncertainty itself marked a sharp reset from the previous market.

Friedberg saw CAR-T as the episode’s most consequential technology story: an FDA-approved multiple-myeloma therapy showed very high response rates using engineered immune cells. He argued today’s roughly $400,000–$450,000 treatment price could eventually fall below $5,000, opening the same platform to solid tumors and autoimmune disease. (fda.gov)